Shanghai North Carolina passed the acceptance of industry-university-research innovation project
Release time:
2020-07-22
Shanghai North Carolina Passed Acceptance of Industry-University-Research Innovation Project
News Recently, the "Research on Innovation and Creation of Heterocyclic Series Molecular Targeted Drugs with Quinazoline as the Core" project declared by Shanghai North Carolina Pharmaceutical Technology Co., Ltd. successfully passed the acceptance of industry-university-research projects of enterprises in the region organized by Shanghai Songjiang District Economic Committee.
"Research on Innovation and Creation of Heterocyclic Series Molecular Targeted Drugs with Quinazoline as the Core" is jointly researched by Shanghai Beika and Xie Hexin Research Group of School of Pharmacy of East China University of Science and Technology, aiming at the research and development of process improvement, quality, cost control and impurities of ceritinib bulk drug and its intermediate products, overcoming the shortcomings of existing technologies, the formation of novel, green, with cost control and quality advantages of new processes, new products. The development of this project has accelerated the progress of scientific and technological innovation and technology transformation, which is conducive to solving technical problems, cultivating innovative talents, improving innovation efficiency, building R & D teams, and promoting the transformation of R & D results through joint research with the resources of universities and enterprises.
According to the Implementation Rules of "Several Opinions on Promoting Innovation and Entrepreneurship to Promote Songjiang Economic Transformation and Upgrading" and "Songjiang District Industrial Technology Innovation Management Measures", Songjiang District Economic Commission invited people from the National Traditional Chinese Medicine Pharmaceutical Engineering Technology Research Center, Shanghai Animal Husbandry and Veterinary Research Institute and other units 4 experts checked and accepted the project.
During the project period, Shanghai North Carolina not only completed various tasks such as the research and development of the project's technical scheme, the optimization and construction of the innovation environment, and the construction of the R & D team, but also carried out the upgrading and transformation of the R & D laboratory, pilot experiment platform, EIA filing and supporting environmental protection treatment facilities, and passed the accreditation of Shanghai High-tech Enterprise and Songjiang Enterprise Technology Center and the review of Shanghai Specialized New Enterprise, the certification of Shanghai academician expert workstation and the acceptance of Shanghai science and technology giant (cultivation) have laid a more solid foundation for the application of subsequent scientific research projects, and also provided valuable experience for Shanghai North Carolina to apply for other scientific research projects. Shanghai North Carolina has opened a new chapter in scientific research development. The person in charge of Shanghai North Carolina said that in the future, Shanghai North Carolina will take advantage of the variety, technology and quality advantages that focus on development, adhere to product research and development innovation, and further build a characteristic brand in the field of small molecule targeted drugs for precision medicine. (Fang Yuyu)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page